Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in parkinson's disease

Journal of Neuroendocrinology

Volumn 23, Issue 6, 2011, Pages 519-524

  Aziz, N A ^a   Pijl, H ^a   Frolich M ^a   Roelfsema, F ^a   Roos, R A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Growth hormone; Hypothalamus; Non motor symptoms; Parkinson's disease; Prolactin; Thyroid stimulating hormone

Indexed keywords

GROWTH HORMONE; PROLACTIN; SOMATOMEDIN C; THYROTROPIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY FAT; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ENTROPY; FEMALE; FLUOROIMMUNOASSAY; FREE THYROXINE INDEX; GROWTH HORMONE RELEASE; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN DENATURATION; REGULATORY MECHANISM; REM SLEEP; SLEEP; THYROTROPIN RELEASE;

CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLOME; MIDDLE AGED; PARKINSON DISEASE; PROLACTIN; SLEEP; THYROID HORMONES; THYROTROPIN;

EID: 79955957861     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2011.02134.x     Document Type: Article

References (31)

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
2. Aziz NA, van der Marck MA, Pijl H, Olde Rikkert MG, Bloem BR, Roos RA. Weight loss in neurodegenerative disorders. J Neurol 2008; 255: 1872-1880.
3. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, Van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130: 1577-1585.
4. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007; 130: 1586-1595.
5. Lopez M, Tena-Sempere M, Dieguez C. Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes). Front Neuroendocrinol 2010; 31: 113-127.
6. Pissios P, Bradley RL, Maratos-Flier E. Expanding the scales: the multiple roles of MCH in regulating energy balance and other biological functions. Endocr Rev 2006; 27: 606-620.
7. Kok SW, Roelfsema F, Overeem S, Lammers GJ, Frolich M, Meinders AE, Pijl H. Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab 2005; 288: E892-E899.
8. Overeem S, Kok SW, Lammers GJ, Vein AA, Frolich M, Meinders AE, Roelfsema F, Pijl H. Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. Am J Physiol Endocrinol Metab 2003; 284: E641-E647.
9. Bellomo G, Santambrogio L, Fiacconi M, Scarponi AM, Ciuffetti G. Plasma profiles of adrenocorticotropic hormone, cortisol, growth hormone and prolactin in patients with untreated Parkinson's disease. J Neurol 1991; 238: 19-22.
10. Volpi R, Caffarra P, Scaglioni A, Boni S, Saginario A, Chiodera P, Coiro V. Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. Neuropsychobiology 1997; 35: 79-83.
11. Cusimano G, Capriani C, Bonifati V, Meco G. Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients. Acta Neurol Scand 1991; 83: 145-150.
12. Kostic VS, Lecic D, Doder M, Marinkovic J, Filipovic S. Prolactin and cortisol responses to fenfluramine in Parkinson's disease. Biol Psychiatry 1996; 40: 769-775.
13. Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: description and validation using synthetic data. Anal Biochem 2008; 381: 8-17.
14. Willis GL. Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev Neurosci 2008; 19: 245-316.
15. Vigas M, Celko J, Koska J. Role of body temperature in exercise-induced growth hormone and prolactin release in non-trained and physically fit subjects. Endocr Regul 2000; 34: 175-180.
16. Cauter vanEV, Kerkhofs M, Caufriez A, Van OA, Thorner MO, Copinschi G. A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day. J Clin Endocrinol Metab 1992; 74: 1441-1450.
17. Aziz NA, Pijl H, Frolich M, Schroder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease. Eur J Neurol 2010; 17: 280-288.
18. Aziz NA, Pijl H, Frolich M, Roelfsema F, Roos RA. Altered thyrotropic and lactotropic axes regulation in Huntington's disease. Clin Endocrinol (Oxf) 2010; 73: 540-545.
19. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 2010; 81: 536-538.
20. Murri L, Iudice A, Muratorio A, Polleri A, Barreca T, Murialdo G. Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea. Eur Neurol 1980; 19: 198-206.
21. Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB. Prolactin secretion in Parkinson disease. Neurology 1981; 31: 1356-1359.
22. Winkler AS, Landau S, Chaudhuri KR. Serum prolactin levels in Parkinson's disease and multiple system atrophy. Clin Auton Res 2002; 12: 393-398.
23. Agnoli A, Baldassarre M, Ruggieri S, Falaschi P, Urso RD, Rocco A. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response. J Neural Transm 1981; 51: 123-134.
24. Franceschi M, Camerlingo M, Perego L, Bottacchi E, Truci G, Mamoli A. Tuberoinfundibular dopaminergic function in Parkinson's disease. Eur Neurol 1988; 28: 117-119.
25. Kostic VS, Marinkovic Z, Filipovic S, Momcilovic D. Function of dopamine receptors in young-onset Parkinson's disease: prolactin response. Mov Disord 1993; 8: 227-229.
26. Laihinen A, Rinne UK. Function of dopamine receptors in Parkinson's disease: prolactin responses. Neurology 1986; 36: 393-395.
27. Martignoni E, Horowski R, Liuzzi A, Costa A, Dallabonzana D, Cozzi R, Attanasio R, Rainer E, Nappi G. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Clin Neuropharmacol 1996; 19: 72-80.
28. Vogel HP, Ketsche R. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy. J Neurol 1986; 233: 149-152.
29. Conte-Devolx B, Grino M, Nieoullon A, Javoy-Agid F, Castanas E, Guillaume V, Tonon MC, Vaudry H, Oliver C. Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus. Neurosci Lett 1985; 56: 217-222.
30. Pique L, Jegou S, Bertagna X, Javoy-Agid F, Seurin D, Proeschel MF, Girard F, Agid Y, Vaudry H, Luton JP. Pro-opiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients. Neurosci Lett 1985; 54: 141-146.
31. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978; 3: 129-133.